Cutler Group’s Blueprint Medicines BPMC Stock Holding History

Cutler Group’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-4,000	Closed	-$20K	–	4987
2022 Q1	$20K	Buy	+4,000	New	+$287K	﹤0.01%	3052
2021 Q1	–	Sell	-5,200	Closed	-$6K	–	5646
2020 Q4	$6K	Hold	5,200	–	–	﹤0.01%	3507
2020 Q3	$29K	Buy	+5,200	New	+$400K	﹤0.01%	2173
2020 Q1	–	Sell	-1,700	Closed	-$33K	–	4033
2019 Q4	$33K	Sell	1,700 -10,000	-85%	-$749K	﹤0.01%	1906
2019 Q3	$116K	Buy	11,700 +9,100	+350%	+$787K	0.01%	995
2019 Q2	$31K	Sell	2,600 -2,400	-48%	-$198K	﹤0.01%	1887
2019 Q1	$40K	Buy	5,000 +2,500	+100%	+$185K	﹤0.01%	1575
2018 Q4	$69K	Buy	+2,500	New	+$152K	0.01%	1284
2018 Q2	–	Sell	-3,000	Closed	-$18K	–	4215
2018 Q1	$18K	Buy	+3,000	New	+$259K	﹤0.01%	2354
2017 Q2	–	Sell	-32,000	Closed	-$98K	–	6367
2017 Q1	$98K	Buy	32,000 +26,400	+471%	+$945K	﹤0.01%	1753
2016 Q4	$7K	Buy	+5,600	New	+$169K	﹤0.01%	4563

Other funds holding BPMC

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Cutler Group's BPMC Position: Q4 2023 in Review

Cutler Group sold out of Blueprint Medicines (BPMC) in Q4 2023, closing a stake of 1,000 shares — an estimated $50K sold.

Cutler Group first reported a position in BPMC in Q1 2017 and held it in 21 quarters. The position peaked at $456K in Q1 2017. 259 funds tracked by Wall St. Rank hold BPMC as of Q4 2023.

Cutler Group reported no remaining Blueprint Medicines position as of Q4 2023 after selling out during the quarter.
Cutler Group sold 1,000 Blueprint Medicines shares in Q4 2023, an estimated $50K.
Cutler Group first reported a position in Blueprint Medicines in Q1 2017 and held it in 21 quarters.
Cutler Group's Blueprint Medicines position peaked at $456K in Q1 2017.
259 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.